ES2507517T3 - Agente profiláctico o terapéutico para trastorno de déficit de atención con hiperactividad - Google Patents
Agente profiláctico o terapéutico para trastorno de déficit de atención con hiperactividad Download PDFInfo
- Publication number
- ES2507517T3 ES2507517T3 ES09705629.5T ES09705629T ES2507517T3 ES 2507517 T3 ES2507517 T3 ES 2507517T3 ES 09705629 T ES09705629 T ES 09705629T ES 2507517 T3 ES2507517 T3 ES 2507517T3
- Authority
- ES
- Spain
- Prior art keywords
- prophylactic
- therapeutic agent
- attention deficit
- hyperactivity disorder
- deficit hyperactivity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Abstract
Un agente profiláctico o terapéutico para uso en el tratamiento o prevención del trastorno de déficit de atención con hiperactividad, que comprende (S)-N-[2-(1,6,7,8-tetrahidro-2H-indeno[5,4-b]furan-8-il)etil]propionamida como ingrediente activo.
Description
Claims (1)
-
imagen1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008022059 | 2008-01-31 | ||
JP2008022059 | 2008-01-31 | ||
PCT/JP2009/051658 WO2009096564A1 (ja) | 2008-01-31 | 2009-01-30 | 注意欠陥・多動性障害の予防または治療剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2507517T3 true ES2507517T3 (es) | 2014-10-15 |
Family
ID=40912907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES09705629.5T Active ES2507517T3 (es) | 2008-01-31 | 2009-01-30 | Agente profiláctico o terapéutico para trastorno de déficit de atención con hiperactividad |
Country Status (8)
Country | Link |
---|---|
US (2) | US20100331402A1 (es) |
EP (1) | EP2248808B1 (es) |
JP (2) | JP5588177B2 (es) |
CN (1) | CN101983193B (es) |
CA (1) | CA2713598C (es) |
ES (1) | ES2507517T3 (es) |
SG (1) | SG185969A1 (es) |
WO (1) | WO2009096564A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103989643B (zh) * | 2013-07-26 | 2018-10-30 | 武汉先路医药科技有限公司 | 含有雷美替胺和共聚维酮的片剂 |
CN104546746A (zh) * | 2013-10-28 | 2015-04-29 | 南京长澳医药科技有限公司 | 一种雷美替胺片剂及其制备工艺 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2884153B2 (ja) | 1996-03-08 | 1999-04-19 | 武田薬品工業株式会社 | 三環性化合物、その製造法および剤 |
US6034239A (en) * | 1996-03-08 | 2000-03-07 | Takeda Chemical Industries, Ltd. | Tricyclic compounds, their production and use |
SK283970B6 (sk) * | 1996-03-08 | 2004-06-08 | Takeda Chemical Industries, Ltd. | Tricyklické zlúčeniny, spôsob výroby a farmaceutický prípravok ich obsahujúci |
CA2357114C (en) * | 2001-03-22 | 2010-06-29 | Pooger Properties Ltd. | Use of melatonin in the manufacture of a medicament for treating attention deficit hyperactive disorder |
CA2445843A1 (en) * | 2001-05-01 | 2002-11-07 | H. Lundbeck A/S | The use of enantiomeric pure escitalopram |
WO2004028532A1 (en) * | 2002-09-26 | 2004-04-08 | Pooger Properties Limited | Combined use of methylphenidate and melatonin for treating attention-deficit hyperactive disorder |
JP4571645B2 (ja) * | 2003-12-02 | 2010-10-27 | ファルマニューロブースト エン.フェー. | D4および5−ht2aアンタゴニスト、逆アゴニストまたは部分アゴニストの使用 |
JP2008514689A (ja) * | 2004-10-01 | 2008-05-08 | ニューロキュア リミテッド | Adhd、cfs、fmおよび鬱病の処置のためのロフェプラミンの薬学的な組成物の使用 |
CA2580221A1 (en) * | 2004-10-05 | 2006-04-13 | Merz Pharma Gmbh & Co. Kgaa | Novel cyclic and acyclic propenones for treating cns disorders |
JP5259181B2 (ja) * | 2005-04-04 | 2013-08-07 | 武田薬品工業株式会社 | うつ病または不安神経症の予防または治療剤 |
CA2620333A1 (en) * | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
CA2621560A1 (en) * | 2005-09-07 | 2007-03-15 | Braincells, Inc. | Modulation of neurogenesis by hdac inhibition |
CA2523399A1 (en) * | 2005-10-14 | 2007-04-14 | Institut Pasteur | Genetic variations associated with psychiatric disorders |
WO2008035177A2 (en) * | 2006-09-18 | 2008-03-27 | Copharm | Combination of mt1 and mt2 melatonin receptor agonists and a norepinephrine/dopamine reuptake inhibitor |
WO2008083204A2 (en) * | 2006-12-28 | 2008-07-10 | Braincells, Inc. | Modulation of neurogenesis by melatoninergic ligands |
-
2009
- 2009-01-30 CA CA2713598A patent/CA2713598C/en active Active
- 2009-01-30 JP JP2009551626A patent/JP5588177B2/ja active Active
- 2009-01-30 WO PCT/JP2009/051658 patent/WO2009096564A1/ja active Application Filing
- 2009-01-30 US US12/865,689 patent/US20100331402A1/en not_active Abandoned
- 2009-01-30 SG SG2012082293A patent/SG185969A1/en unknown
- 2009-01-30 ES ES09705629.5T patent/ES2507517T3/es active Active
- 2009-01-30 EP EP09705629.5A patent/EP2248808B1/en active Active
- 2009-01-30 CN CN200980112044.0A patent/CN101983193B/zh active Active
-
2014
- 2014-03-20 JP JP2014059089A patent/JP2014141511A/ja not_active Abandoned
-
2016
- 2016-07-14 US US15/210,070 patent/US20170128409A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20100331402A1 (en) | 2010-12-30 |
JP5588177B2 (ja) | 2014-09-10 |
JPWO2009096564A1 (ja) | 2011-05-26 |
CN101983193B (zh) | 2014-03-12 |
CA2713598A1 (en) | 2009-08-06 |
CA2713598C (en) | 2016-07-05 |
WO2009096564A1 (ja) | 2009-08-06 |
EP2248808A4 (en) | 2011-11-02 |
CN101983193A (zh) | 2011-03-02 |
EP2248808A1 (en) | 2010-11-10 |
SG185969A1 (en) | 2012-12-28 |
JP2014141511A (ja) | 2014-08-07 |
US20170128409A1 (en) | 2017-05-11 |
EP2248808B1 (en) | 2014-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2649340T3 (es) | Administración de fármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer | |
ES2557303T3 (es) | Agente terapéutico para la estenosis del canal espinal | |
BR112012022797A2 (pt) | composição farmacêutica resistente a álcool, e, método para tratar uma doença com uma formulação de agente ativo resistente a álcool | |
ES2487496T3 (es) | Agente para aliviar el síndrome metabólico | |
AR059390A1 (es) | Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopausicos | |
CL2009000349A1 (es) | Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer. | |
ES2564172T3 (es) | Utilización de una composición cosmética para el cuidado de las pieles grasas | |
AR060880A1 (es) | Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual | |
CL2012002551A1 (es) | Combinacion farmaceutica que comprende por lo menos un 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol de fórmula (i) y por lo menos un antagonista de nmda; composicion farmaceutica; y uso para el tratamiento del dolor. | |
UY34775A (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis múltiple | |
CY1121852T1 (el) | Μορφοποιησεις και μεθοδοι παρασκευης μορφοποιησεων για χρηση στον καθαρισμο του παχεος εντερου | |
CL2008002545A1 (es) | Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor. | |
CO7240418A2 (es) | Apósito con una liberación prolongada de agentes activos | |
CO7131368A2 (es) | (r)-nifuratel, su uso para el tratamiento de infecciones y síntesis de (r) y (s)-nifuratel | |
ECSP10010553A (es) | Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre | |
CL2009001841A1 (es) | Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto. | |
ES2528366T3 (es) | Citicolina para el tratamiento del glaucoma | |
CL2012000097A1 (es) | Compuestos derivados de 3-fenoximetilpirrolidina, inhibidores de la recaptacion de serotonina-norepinefrina; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos del dolor, depresion, entre otros. | |
ES2616035T3 (es) | Preparación para su uso en la profilaxis y el tratamiento de osteoporosis atípica | |
CL2008002758A1 (es) | Composicion que comprende al menos un principio activo laxante y al menos un principio activo antiespumante; uso para el tratamiento del estrenimiento. | |
BR112018014723A2 (pt) | fantasmas bacterianos para o tratamento de câncer | |
NI201000212A (es) | Dronedarona para la prevención de la cardioversión. | |
DOP2010000327A (es) | Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento de nivel de creatinina debido a la administracion de dronedarona | |
ES2507517T3 (es) | Agente profiláctico o terapéutico para trastorno de déficit de atención con hiperactividad | |
CL2008000965A1 (es) | Composicion farmaceutica que comprende un agente antiinflamatorio no esteroideo y un analgesico opiaceo, y su uso para el tratamiento del dolor. |